Valiant LaboratoriesNSE:VALIANTLAB -0.06%51 Interest Coverage is 1.87 as of Mar. 2026, which is 98% below its 10-year median of 79.47. GuruFocus rates NSE:VALIANTLAB with a GF Score™ of 51/100 and a GF Value™ of ₹103.25 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 685 Drug Manufacturers companies, Valiant Laboratories ranks worse than 99.12% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Valiant Laboratories's
Operating Income
for the
three
months ended in Mar. 2026 was ₹19 Mil. Valiant Laboratories's Interest Expense for the
three
months ended in Mar. 2026 was ₹-10 Mil.
Valiant Laboratories's interest coverage for the quarter that ended in Mar. 2026 was 1.87.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Valiant Laboratories's Interest Coverage or its related term are showing as below:
NSE:VALIANTLAB'
s Interest Coverage Range Over the Past 10 Years
Min: 0.18 Med: 79.47 Max: 548.01
Current: 0.19
NSE:VALIANTLAB's Interest Coverage is ranked worse than 99.12% of 685
companies
in the Drug Manufacturers industry
Industry Median: 12.78
vs NSE:VALIANTLAB: 0.19
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Valiant Laboratories Interest Coverage Related Terms
Valiant Laboratories Interest Coverage Historical Data
* Premium members only.
The historical data trend for Valiant Laboratories's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
NSE:VALIANTLAB vs ZTS: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Valiant Laboratories's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valiant Laboratories Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Valiant Laboratories's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Valiant Laboratories's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Valiant Laboratories (NSE:VALIANTLAB) has a Interest Coverage of 1.87 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Valiant Laboratories and its competitors. This is 98% below median its historical median of 79.47. Over the past decade, Valiant Laboratories' Interest Coverage has ranged from 0.18 to 548.01. According to the industry distribution chart, Valiant Laboratories ranks #679 out of 685 companies in the Drug Manufacturers industry, placing it in the top 99.1%.
Is Valiant Laboratories' Interest Coverage too high?
Valiant Laboratories' current Interest Coverage of 1.87 is 98% below median its 10-year median of 79.47. Over the past 10 years, this metric has ranged from a low of 0.18 to a high of 548.01. The Drug Manufacturers industry median Interest Coverage is 12.78. Valiant Laboratories' value of 1.87 is 85.4% below this industry median. Based on the distribution chart, Valiant Laboratories ranks #679 out of 685 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Valiant Laboratories has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Valiant Laboratories' Interest Coverage compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Valiant Laboratories ranks #679 out of 685 companies for Interest Coverage. This places Valiant Laboratories in the lower half of its industry. The industry median Interest Coverage is 12.78. Valiant Laboratories' value of 1.87 is 85.4% below this benchmark. Historically, Valiant Laboratories' own Interest Coverage has ranged from 0.18 to 548.01 over the past decade. While the company's 10-year median is 79.47 vs. the industry median of 12.78, Valiant Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.78, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Valiant Laboratories's current Interest Coverage of 1.87 is 85.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Valiant Laboratories and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Valiant Laboratories's current Interest Coverage is 1.87, which is 98% below median its own 10-year median of 79.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valiant Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Valiant Laboratories (NSE:VALIANTLAB) is currently considered Possible Value Trap. The stock's GF Value™ is ₹103.25, compared to a current price of ₹68.00 — trading 34.1% below its estimated fair value. The current Interest Coverage is 1.87, which is 98% below median its 10-year median of 79.47 and 85.4% below the Drug Manufacturers industry median of 12.78. Valiant Laboratories' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Valiant Laboratories (NSE:VALIANTLAB), the current Interest Coverage is 1.87 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Valiant Laboratories (NSE:VALIANTLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Valiant Laboratories stock appears to be undervalued.
The current stock price of ₹68.00 is trading 34.1% below its estimated GF Value™ of ₹103.25.
GuruFocus considers Valiant Laboratories to be Possible Value Trap.
Key valuation signals for NSE:VALIANTLAB:
Interest Coverage: 1.87 (98% below median its 10-year median of 79.47)
GF Value™: ₹103.25 vs. price of ₹68.00 (34.1% below fair value)
Industry Position: 85.4% below the Drug Manufacturers median (#679 of 685)
No single metric tells the full story. See the NSE:VALIANTLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Valiant Laboratories Ltd is an Active Pharmaceutical Ingredient (API)/Bulk Drug manufacturing company with having focus on manufacturing Paracetamol. Paracetamol is one of the widely used analgesics globally and is recommended as the first-line therapy in pain conditions by the World Health Organization. Paracetamol has several applications such as usage in the treatment of headaches, muscle aches, arthritis, backaches, toothaches, colds, and fever. It manufactures Paracetamol in various grades such as IP/BP/EP/USP, as per the pharmacopeia requirements of its customers.
51GF Score
Get the complete analysis for NSE:VALIANTLAB
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:VALIANTLAB has been successfully added to your 
